The Clinical Imperative for Advanced Hemoglobin-Based Oxygen Carriers

Severe ischemic conditions and massive hemorrhage demand rapid restoration of cellular oxygenation. Consequently, acute care physicians often confront the severe biological consequences of tissue hypoxia. Ischemia-reperfusion injury and acute blood loss create complex pathological cascades. In these critical states, oxygen deprivation triggers energetic collapse and rapid cellular death. Subsequently, reoxygenation provokes an aggressive burst of reactive oxygen species. These toxic radicals destroy lipid membranes, damage nuclear DNA, and impair microvascular perfusion. Therefore, standard red blood cell transfusions face clear logistical and biological constraints during sudden crises. Conventional hemoglobin-based oxygen carriers offer temporary tissue oxygenation during acute anemia. However, acellular hemoglobin frequently intensifies oxidative damage through spontaneous autoxidation and iron release. Free hemoglobin generates cytotoxic ferryl species and depletes endogenous nitric oxide. As a result, unshielded carriers frequently trigger systemic vasoconstriction and endothelial injury. To overcome these critical bottlenecks, bioengineers are designing next-generation therapeutic platforms. Encapsulating hemoglobin within protective nanostructures shields surrounding tissues while enabling gas diffusion. Moreover, integrating catalytic antioxidants directly within the nanocarrier can neutralize damaging free radicals at the point of release. This dual approach addresses the root mechanisms of reperfusion damage.

Engineering MOF Nanocages: The ZIF-90 Encapsulation Strategy

To construct resilient carriers, material scientists leverage porous metal-organic frameworks. Specifically, zeolitic imidazolate framework-90 serves as a sophisticated protective nanocage. Investigators synthesize ZIF-90 by coordinating zinc ions with imidazole-2-carboxaldehyde linkers. This mild, aqueous synthetic process permits the biomimetic mineralization of native hemoglobin. As a result, the crystalline framework securely traps hemoglobin molecules within uniform nanoscale pores. The protective lattice prevents molecular aggregation and limits uncoordinated iron degradation. Furthermore, the defined porous channels permit unhindered diffusion of molecular oxygen. Hemoglobin molecules within the framework retain their tertiary structure and reversible gas-binding capacity. Importantly, the metal-organic shell protects the encapsulated protein against premature enzymatic digestion. However, naked framework nanoparticles lack the enzymatic machinery required to counteract severe oxidative environments. Endogenous red blood cells rely on internal enzymes to eliminate cytotoxic peroxides. Without comparable defense mechanisms, synthetic carriers remain vulnerable to environmental oxidative degradation. Therefore, researchers incorporated artificial catalytic enzymes directly onto the outer nanoparticle surfaces. These engineered catalytic particles mimic endogenous protective enzymes. Consequently, the hybrid architecture establishes a multi-tiered defense against physiological oxidative stress.

Integrating Platinum and Cerium Oxide Nanozymes for Catalytic Defense

To mimic endogenous antioxidant defenses, researchers functionalized the framework surfaces with catalytic nanozymes. Nanozymes are nanomaterials that display intrinsic enzyme-mimicking catalytic activity. In this platform, scientists evaluated cerium oxide and platinum nanoparticles. Free cerium oxide nanozymes exhibit potent superoxide dismutase-like activity. They efficiently intercept harmful superoxide anions and convert them into hydrogen peroxide. Meanwhile, platinum nanozymes deliver robust catalase-like and peroxidase-like catalytic activity. Consequently, platinum actively degrades hydrogen peroxide into harmless water and oxygen molecules. Investigators tested single-nanozyme formulations alongside dual-nanozyme hybrid systems. Spectrophotometric assays with WST-1 reagents confirmed rapid superoxide scavenging across functionalized platforms. Furthermore, the nanozyme-coated nanoparticles substantially outperformed unmodified ZIF-90 controls in eliminating radical cascades. Interestingly, hemoglobin itself displays intrinsic catalase-like activity during peroxide exposure. Therefore, encapsulated hemoglobin actively contributed to peroxide decomposition alongside the surface platinum nanozymes. This synergistic catalytic response prevents the accumulation of cytotoxic lipid hydroperoxides. Accordingly, the engineered system successfully replicates the primary antioxidant pathways found in human erythrocytes.

The Redox Dilemma: Reconciling Oxygen Release with Free Radical Scavenging

Engineering dual-function nanocarriers revealed a complex physicochemical trade-off between oxygen affinity and antioxidant power. Specifically, platinum-functionalized nanoparticles preserved reliable oxygen-release kinetics under harsh oxidative stress. Platinum nanozymes effectively shielded the heme center without perturbing iron oxidation states. In sharp contrast, cerium oxide nanoparticles introduced unexpected functional challenges. Higher nominal concentrations of cerium oxide markedly improved superoxide elimination. However, elevated ceria concentrations simultaneously impaired oxygen-unloading capacity. Spectroscopic evaluations demonstrated that excessive cerium oxide promotes unfavorable redox interactions with the encapsulated iron. As a result, the carrier oxidizes functional ferrous hemoglobin into inactive ferric methemoglobin. Methemoglobin cannot bind or deliver physiological oxygen to hypoxic tissues. Furthermore, the dual cerium-platinum formulation achieved superior superoxide dismutation but failed to enhance net oxygen delivery. Thus, maximizing catalytic antioxidant loading does not inevitably yield superior clinical efficacy. Instead, developers must balance redox-scavenging activity against gas-transport preservation. Consequently, future nanocarrier designs require meticulous tuning of nanozyme surface densities.

Translational Hurdles and the Road to Clinical Blood Substitutes

Despite demonstrating remarkable dual functionality, these experimental formulations face notable translational hurdles. Crucially, the current ZIF-90 formulations demonstrated limited colloidal stability when exposed to standard cell-culture media. Serum electrolytes and coordinating amino acids accelerate framework degradation in physiological fluids. Therefore, researchers categorize these systems as cell-free proof-of-concept formulations requiring robust stabilization. Before initiating biological evaluations, researchers must reinforce the outer structural shell. Applying polyethylene glycol coatings or cross-linked albumin layers could enhance serum longevity. Alternatively, cloaking nanoparticles with extracted erythrocyte membranes offers immune evasion and prolonged circulatory retention. In emergency medicine and critical care, stable blood substitutes could transform resuscitation protocols. Synthetic carriers do not require blood typing or cold-chain logistics. Consequently, emergency medical teams could rapidly administer these formulations during severe trauma or disaster relief. Additionally, myocardial infarction and stroke care would benefit from targeted reperfusion without oxidative injury. Continued optimization will bridge the critical divide between material synthesis and clinical applications.

Frequently Asked Questions

What are the primary clinical advantages of nanozyme-functionalized hemoglobin-based oxygen carriers?

Nanozyme-functionalized hemoglobin-based oxygen carriers simultaneously resolve severe tissue hypoxia and reduce secondary reperfusion injury. Conventional carriers deliver molecular oxygen but often provoke oxidative tissue damage and vasoconstriction through free radical generation. By incorporating catalytic nanozymes such as platinum or cerium oxide, these platforms actively dismantle toxic superoxide and hydrogen peroxide radicals. Consequently, they protect microvascular endothelial function and preserve cellular viability during acute resuscitation in trauma, stroke, and organ transplantation procedures.

Why did higher concentrations of cerium oxide nanozymes impair oxygen delivery?

Although cerium oxide nanozymes exhibit outstanding superoxide dismutase-like activity, excessive nominal concentrations trigger adverse redox interactions with hemoglobin. Specifically, reactive cerium species oxidize the functional ferrous iron in the heme prosthetic group into inactive ferric iron, forming methemoglobin. Because methemoglobin cannot reversibly bind or release molecular oxygen, high ceria concentrations compromise oxygen transport. Therefore, bioengineers must strictly balance antioxidant catalytic efficiency against heme redox stability to ensure reliable therapeutic gas delivery.

What modifications are required before these metal-organic frameworks can enter clinical trials?

The current ZIF-90 nanocarriers exhibit rapid degradation when incubated in physiological fluids and cell-culture media. To enable in vivo testing, researchers must implement surface stabilization strategies that prevent premature matrix dissolution. Applying biocompatible polyethylene glycol coatings, cross-linked human serum albumin, or natural erythrocyte membranes can provide structural protection. Furthermore, these surface modifications shield particles from premature reticuloendothelial clearance, reduce complement activation, and ensure sustained systemic circulation during acute clinical resuscitations.

Disclaimer: This content is for informational and educational purposes only... Refer to the latest local and national guidelines for clinical practice.

References

Douka D et al. Nanozyme-functionalized hemoglobin-based oxygen carriers for combined oxygen delivery and reactive oxygen species scavenging. J Mater Chem B. 2026 Nov 06. doi: 10.1039/d6tb01213b. PMID: 42990078.

Douka D, Pablo-Sainz-Ezquerra AM, Jakljevič E, et al. Nanozymes for Advanced Hemoglobin-Based Oxygen Carriers: Applications in Blood Substitution, Wound Healing, Antitumor Therapy, and Beyond. Adv Sci (Weinh). 2026;13(36):e24094.

Coll-Satue C, Bishnoi S, Chen J, Hosta-Rigau L. Stepping stones to the future of haemoglobin-based blood products: clinical, preclinical and innovative examples. Biomater Sci. 2021;9(4):1135-1152.

Jakljevič E, Bor G, Arnholdt L, Coll-Satue C, Hosta-Rigau L. Restoring normoxia in hypoxic cancer cells via hemoglobin-loaded MOF nanoparticles. Int J Biol Macromol. 2025;285:148520.